dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Serrano Garcia, César |
dc.contributor.author | Mariño-Enríquez, Adrián |
dc.contributor.author | Tao, Derrick L. |
dc.contributor.author | Ketzer, Julia |
dc.contributor.author | Eilers, Grant |
dc.contributor.author | Zhu, Meijun |
dc.date.accessioned | 2021-03-18T08:52:39Z |
dc.date.available | 2021-03-18T08:52:39Z |
dc.date.issued | 2019-03 |
dc.identifier.citation | Serrano C, Mariño-Enríquez A, Tao DL, Ketzer J, Eilers G, Zhu M, et al. Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours. Br J Cancer. 2019 Mar;120(6):612–20. |
dc.identifier.issn | 1532-1827 |
dc.identifier.uri | https://hdl.handle.net/11351/5770 |
dc.description | Marcadors predictius; Sarcoma; Tumors estromals gastrointestinals |
dc.description.sponsorship | This work was supported in part by an ASCO Young Investigator Award (CS), a Spanish Society of Medical Oncology Translational Award (CS), Río Hortega-ISCIII CM14/00241 (CS) FERO Foundation (CS), US National Institutes of Health grants 1P50CA127003 (GDD, ES, JAF), 1P50CA168512 (JAF, AME), GIST Cancer Research Fund (JAF, MCH), Life Raft Group (JAF, MCH, SB), V Foundation Translational Grant (MCH), VA Merit Review Award (2I01BX000338–05) (MCH) and the Deutsche Krebshilfe (SB). CS acknowledges to the Cellex Foundation for providing facilities and equipment. |
dc.language.iso | eng |
dc.publisher | Nature Publishing Group |
dc.relation.ispartofseries | British Journal of Cancer;120(6) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Tracte gastrointestinal - Càncer |
dc.subject | Medicaments antineoplàstics |
dc.subject | Resistència als medicaments |
dc.subject.mesh | Gastrointestinal Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Drug Resistance, Neoplasm |
dc.title | Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1038/s41416-019-0389-6 |
dc.subject.decs | neoplasias gastrointestinales |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | resistencia a los antineoplásicos |
dc.relation.publishversion | https://www.nature.com/articles/s41416-019-0389-6 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Serrano C] Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, 20 Shattuck Street, Thorn 528, Boston, MA, USA. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Sarcoma Translational Research Laboratory, Vall d’Hebron Institute of Oncology, Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Mariño-Enríquez A, Tao DL, Eilers G, Zhu M] Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, 20 Shattuck Street, Thorn 528, Boston, MA, USA. [Ketzer J] Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany |
dc.identifier.pmid | 30792533 |
dc.identifier.wos | 000461700900007 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |